Detecting sepsis using blood fluorescence technology
Detection of Sepsis Occurrence by Using Blood Fluorescence
This study is testing a new blood test that uses special technology to see if it can quickly spot early signs of sepsis in patients before serious damage happens.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06745115 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore a novel blood fluorescence metabolite analyzer designed to detect early signs of sepsis by identifying inflammatory free radicals in the blood. By employing a case-control methodology, the study will compare blood samples from healthy individuals, septic patients, and non-septic severe patients to assess the analyzer's sensitivity and accuracy. The goal is to enable rapid diagnosis of sepsis before organ damage occurs, potentially reducing mortality rates associated with this condition. The study will involve frequent screenings of blood samples to validate the effectiveness of this reagent-free technology.
Who should consider this trial
Good fit: Ideal candidates include adults with confirmed infections exhibiting qSOFA scores of 2 or higher, as well as healthy individuals for comparison.
Not a fit: Patients who are minors, pregnant, or have mental illnesses will not benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the time to diagnose sepsis, leading to timely interventions and improved patient outcomes.
How similar studies have performed: While there have been studies exploring early detection methods for sepsis, this specific approach using blood fluorescence technology is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy control group: Individuals who are physically healthy with no underlying diseases and have not been hospitalized within the past two years. Recruitment for healthy volunteers will be conducted through notices and online media. 2. Sepsis Experimental Group: Patients with confirmed infections, having qSOFA ≥ 2 and SOFA ≥ 2, will be screened and confirmed by a physician to meet the inclusion criteria. 3. Non-septic Severe Control Group: Patients with suspected or confirmed infections, having a SOFA score of 1, will be screened and confirmed by a physician to meet the inclusion criteria. Exclusion Criteria: minors, pregnant, individuals with mental illnesses, and other vulnerable groups.
Where this trial is running
Guangzhou, Guangdong
- zhujiang Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Ning Zeng, Doctor
- Email: chen_ning16@foxmail.com
- Phone: 13760694012
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.